A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Local Institution - 0020, Geneva

Local Institution - 0012, Basel

Local Institution - 0021, Sankt Gallen

Local Institution - 0018, Marseille

Local Institution - 0025, Madrid

Local Institution - 0022, Madrid

Local Institution - 0023, Madrid

Local Institution - 0024, Málaga

Local Institution - 0019, Toulouse

Local Institution - 0015, Bordeaux

Local Institution - 0003, Houston

Local Institution - 0014, Villejuif

Local Institution - 0010, Boston

Local Institution - 0001, Hackensack

Local Institution - 0007, Edmonton

Local Institution - 0011, Hamilton

Local Institution - 0005, Ottawa

Local Institution - 0006, Toronto